{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:32:30Z","timestamp":1793521950810,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Math. Biol."],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00285-017-1098-5","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T21:52:48Z","timestamp":1485381168000},"page":"733-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term treatment effects in chronic myeloid leukemia"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3143-304X","authenticated-orcid":false,"given":"Apollos","family":"Besse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lepoutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"key":"1098_CR1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/hon.920","volume":"28","author":"M Breccia","year":"2010","unstructured":"Breccia M, Cannella L, Stefanizzi C et al (2010) Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. Hematol Oncol 28:89\u201392","journal-title":"Hematol Oncol"},{"issue":"20","key":"1098_CR2","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, Bhatia R (2011) Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118(20):5565\u20135572","journal-title":"Blood"},{"issue":"7\u20138","key":"1098_CR3","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.mcm.2010.05.034","volume":"53","author":"J Clairambault","year":"2011","unstructured":"Clairambault J, Gaubert S, Lepoutre T (2011) Circadian rhythm and cell population growth. Math Comput Model 53(7\u20138):1558\u20131567","journal-title":"Math Comput Model"},{"issue":"19","key":"1098_CR4","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1158\/0008-5472.CAN-15-0611","volume":"75","author":"GD Clapp","year":"2015","unstructured":"Clapp GD, Lepoutre T, El Cheikh R, Bernard S, Ruby J, Labussi\u00e8re-Wallet H, Nicolini FE, Levy D (2015) Implication of the autologous immune system in BCR-ABL transcript variations in chronic myelogenous leukemia patients treated with imatinib. Cancer Res 75(19):4053\u20134062","journal-title":"Cancer Res"},{"issue":"10","key":"1098_CR5","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MWN Deininger","year":"2008","unstructured":"Deininger MWN, Goldman JM, Melo JV (2008) The molecular biology of chronic myeloid leukemia. Blood 96(10):3343\u20133356","journal-title":"Blood"},{"issue":"7","key":"1098_CR6","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s11538-009-9500-0","volume":"72","author":"M Doumic-Jauffret","year":"2010","unstructured":"Doumic-Jauffret M, Kim PS, Perthame B (2010) Stability analysis of a simplified yet complete model for chronic myelogenous leukemia. Bull Math Biol 72(7):1732\u20131759","journal-title":"Bull Math Biol"},{"issue":"9","key":"1098_CR7","doi-asserted-by":"crossref","first-page":"e1000503","DOI":"10.1371\/journal.pcbi.1000503","volume":"5","author":"J Foo","year":"2009","unstructured":"Foo J, Drummond MW, Clarkson B, Holyoake TL, Michor F (2009) Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol 5(9):e1000503","journal-title":"PLoS Comput Biol"},{"issue":"11","key":"1098_CR8","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/bjc.2012.142","volume":"106","author":"I Glauche","year":"2012","unstructured":"Glauche I, Horn K, Horn M, Thielecke L, Essers MAG, Trumpp A, Roeder I (2012) Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations. Br J Cancer 106(11):1742\u20131752","journal-title":"Br J Cancer"},{"issue":"1","key":"1098_CR9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan EK, Pearson C, Alcorn MJ, Richmond L, Holyoake TL (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99(1):319\u2013325","journal-title":"Blood"},{"issue":"5","key":"1098_CR10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 32(5):415\u2013423","journal-title":"J Clin Oncol"},{"issue":"7","key":"1098_CR11","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s11538-008-9336-z","volume":"70","author":"PS Kim","year":"2008","unstructured":"Kim PS, Lee PP, Levy D (2008a) A PDE model for imatinib-treated chronic myelogenous leukemia. Bull Math Biol 70(7):1994\u20132016","journal-title":"Bull Math Biol"},{"issue":"6","key":"1098_CR12","doi-asserted-by":"crossref","first-page":"e1000095","DOI":"10.1371\/journal.pcbi.1000095","volume":"4","author":"PS Kim","year":"2008","unstructured":"Kim PS, Lee PP, Levy D (2008b) Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput Biol 4(6):e1000095","journal-title":"PLoS Comput Biol"},{"issue":"3","key":"1098_CR13","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s11538-007-9276-z","volume":"70","author":"PS Kim","year":"2008","unstructured":"Kim PS, Lee PP, Levy D (2008c) Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models. Bull Math Biol 70(3):728\u2013744","journal-title":"Bull Math Biol"},{"issue":"10","key":"1098_CR14","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1371\/journal.pone.0000990","volume":"2","author":"NL Komarova","year":"2007","unstructured":"Komarova NL, Wodarz D (2007) Effect of cellular quiescence on the success of targeted CML therapy. PLoS ONE 2(10):e990","journal-title":"PLoS ONE"},{"issue":"11","key":"1098_CR15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029\u20131035","journal-title":"Lancet Oncol"},{"key":"1098_CR16","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA (2005) Dynamics of chronic myeloid leukaemia. Nature 435:1267\u20131270","journal-title":"Nature"},{"issue":"11","key":"1098_CR17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994\u20131004","journal-title":"N Engl J Med"},{"issue":"26","key":"1098_CR18","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE et al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363(26):2511\u20132521","journal-title":"N Engl J Med"},{"issue":"3","key":"1098_CR19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s11538-008-9373-7","volume":"71","author":"I Roeder","year":"2009","unstructured":"Roeder I, Herberg M, Horn M (2009) An \u201cage\u201d-structured model of hematopoietic stem cell organization with application to chronic myeloid leukemia. Bull Math Biol 71(3):602\u2013626","journal-title":"Bull Math Biol"},{"issue":"10","key":"1098_CR20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2006","unstructured":"Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12(10):1181\u20131184","journal-title":"Nat Med"},{"issue":"10","key":"1098_CR21","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"D\u00a0M Ross","year":"2010","unstructured":"Ross D\u00a0M, Branford S, Seymour J\u00a0F et al (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24(10):1719\u20131724","journal-title":"Leukemia"},{"issue":"1","key":"1098_CR22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M, Mahon FX (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109(1):58\u201360","journal-title":"Blood"},{"issue":"94","key":"1098_CR23","doi-asserted-by":"crossref","first-page":"20140079","DOI":"10.1098\/rsif.2014.0079","volume":"11","author":"T Stiehl","year":"2014","unstructured":"Stiehl T, Baran N, Ho AD, Marciniak-czochra A, Stiehl T, Baran N, Ho AD, Marciniak-czochra A (2014) Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse. J R Soc Interface 11(94):20140079","journal-title":"J R Soc Interface"},{"issue":"3","key":"1098_CR24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","volume":"142","author":"P Valent","year":"2008","unstructured":"Valent P (2008) Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol 142(3):361\u2013378","journal-title":"Br J Haematol"}],"container-title":["Journal of Mathematical Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00285-017-1098-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00285-017-1098-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00285-017-1098-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T02:12:42Z","timestamp":1719022362000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00285-017-1098-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,25]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1007\/s00285-017-1098-5","relation":{},"ISSN":["0303-6812","1432-1416"],"issn-type":[{"value":"0303-6812","type":"print"},{"value":"1432-1416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,25]]}}}